Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers

References

• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. Springer US. 2014;15(2):434–455. .
   PubMed Web of Science ®Google Scholar
• Buttini F, Miozzi M, Balducci AG, et al. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. Int J Pharm. Elsevier. 2014;465:42–51.
   PubMed Web of Science ®Google Scholar
• Ganderton D, Lewis D, Davies R, et al. Modulite®: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med. W.B. Saunders. 2002;96:S3–S8.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Young PM, Buttini F, et al. Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. Eur J Pharm Biopharm. Elsevier. 2014;86:31–37.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. BioMed Central. 2018;19:1–20.
   PubMed Web of Science ®Google Scholar
• Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol. Elsevier. 2017;5:1071–1079.
   Web of Science ®Google Scholar
• Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93:439–446.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. W.B. Saunders. 2011;105:930–938.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, FHC DJ, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. European Respiratory Society. 2011;37:1308–1331.
   PubMed Web of Science ®Google Scholar
• Hatley RHM, Parker J, Pritchard JN, et al. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. J Aerosol Med Pulm Drug Deliv. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA. 2017;30:71–79.
   PubMed Web of Science ®Google Scholar
• Berlinski A, Hollen VD, Pritchard JN, et al. Delay between shaking and actuation of a hydrofluoroalkane fluticasone pressurized metered-dose inhaler. Respir Care. 2018;63:289–293.
   PubMed Web of Science ®Google Scholar
• Michael Y, Snowden MJ, Chowdhry BZ, et al. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm. Elsevier. 2001;221: 165–174.
   PubMed Web of Science ®Google Scholar
• Sukasame N, Boonme P, ScienceAsia TS. Development of budesonide suspensions for use in an HFA pressurized metered dose inhaler. ScienceAsia. 2011;37:31–37.
   Web of Science ®Google Scholar
• Cogan PS. Appropriate use of pressurized metered-dose inhalers for asthma. US Pharm. 2015;40(7):36–41.
   Web of Science ®Google Scholar
• Liu X, Guo C, Chowdhury B, et al. Valved holding chambers and In Vitro metered dose inhaler performance: effects of flow rate and inhalation delay. J Aerosol Med Pulm Drug Deliv. 2017;30:399–410.
   PubMed Web of Science ®Google Scholar
• Prime D, Grant AC, AL SLATER, et al. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, diskhalerinhaler, and Turbuhaler inhaler. J Aerosol Med. 1999;12:75–84.
   PubMedGoogle Scholar
• Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res. Kluwer Academic Publishers-Plenum Publishers. 2000;17:168–174.
   PubMed Web of Science ®Google Scholar
• Doty A, Schroeder J, Vang K, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS Pharm Sci Tech. Springer US. 2018;19:837–844.
   PubMed Web of Science ®Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015–15023.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. Elsevier. 2018;6:747–758.
   PubMed Web of Science ®Google Scholar
• Dunn LJ, Kerwin EM, DeAngelis K, et al. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Pulm Pharmacol Ther. 2020;60:101873.
   PubMed Web of Science ®Google Scholar
• (Cited 2020 May 5). https://www.astrazeneca.com/our-therapy-areas/pearl-therapeutics.html
   Google Scholar
• Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J. European Respiratory Society. 1998;12: 1340–1345.
   PubMed Web of Science ®Google Scholar
• Everard ML, Devadason SG, Summers QA, et al. Factors affecting total and “respirable” dose delivered by a salbutamol metered dose inhaler. Thorax. BMJ Publishing Group Ltd. 1995;50: 746–749.
   PubMed Web of Science ®Google Scholar
• Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax. BMJ Publishing Group Ltd. 1996;51: 981–984.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed Budesonide–Formoterol versus maintenance Budesonide in mild asthma. N Engl J Med. Massachusetts Medical Society. 2018;378:1877–1887.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined Budesonide–Formoterol as needed in mild asthma. N Engl J Med. Massachusetts Medical Society. 2018;378:1865–1876.
   PubMed Web of Science ®Google Scholar
• van Beerendonk I, Mesters I, Mudde AN, et al. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. Taylor & Francis. 2009;35: 273–279.
   Web of Science ®Google Scholar
• Ocakli B, Ozmen I, Acarturk Tuncay E, et al. A comparative analysis of errors in inhaler technique among COPD versus asthma patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2941–2947.
   PubMed Web of Science ®Google Scholar
• Berg E. In Vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med. 1995;8:S–3–S–11.
   PubMedGoogle Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. Elsevier. 2016;150: 394–406.
   PubMed Web of Science ®Google Scholar
• Plaza V, Giner J, Rodrigo GJ, et al. Errors in the use of inhalers by health care professionals: a systematic review. J Allergy Clin Immunol. Elsevier. 2018;6: 987–995.
   Web of Science ®Google Scholar